Trastuzumab - InHER2 and hormone receptor co-positive metastatic breast cancer
Trastuzumab - InHER2 and hormone receptor co-positive metastatic breast cancer
复制标题
DOI：
10.2165/00003495-200767180-00009
复制
发表时间：
2007-01-01
期刊：
影响因子：
11.5
通讯作者：
Perry, Caroline M.
中科院分区：
文献类型：
--
作者：
Orman, Jennifer S.;Perry, Caroline M.
曲妥珠单抗是一种人源化IgG(1)单克隆抗体，可选择性结合人表皮生长因子受体2 (HER2)，抑制HER2依赖性肿瘤中的细胞增殖和存活。在一项针对HER2和激素受体（HR）共阳性转移性乳腺癌的绝经后妇女的随机III期试验中，接受静脉曲妥珠单抗加口服阿那曲唑的患者的中位无进展生存期（主要终点）明显高于单独接受阿那曲唑的患者。总体缓解率和临床获益率也显著更高，曲妥珠单抗联合阿那曲唑与单独使用阿那曲唑相比，到疾病进展的中位时间显著更长。在随机III期试验中，曲妥珠单抗加阿那曲唑联合治疗没有新的或意想不到的不良事件报告。在一项曲妥珠单抗联合来曲唑治疗HER2和HR共阳性转移性乳腺癌绝经后妇女的非对照II期研究中，大多数不良事件的严重程度为轻度或中度。
Trastuzumab is a humanised IgG(1) monoclonal antibody, which selectively binds to the human epidermal growth factor receptor 2 (HER2), inhibiting cell proliferation and survival in HER2-dependent tumours.In a randomised phase III trial in postmenopausal women with HER2 and hormone receptor (HR) co-positive metastatic breast cancer, median progression-free survival (primary endpoint) was significantly longer in patients receiving intravenous trastuzumab plus oral anastrozole than in those receiving anastrozole alone.Overall response rate and clinical benefit rate were also significantly higher, and median time to disease progression was significantly longer with trastuzumab plus anastrozole versus anastrozole alone.There were no reports of new or unexpected adverse events with trastuzumab plus anastrozole combination therapy in the randomised phase III trial.In a noncomparative phase II study of trastuzumab plus letrozole in postmenopausal women with HER2 and HR co-positive metastatic breast cancer, the majority of adverse events were mild or moderate in severity.